α-Aryloxybenzyl
analogues of morpholine are a significant
class of compounds because of their influence on the central nervous
system (CNS), with particular concentration on their antidepressant
potency. (±)-Reboxetine, an example of such α-aryloxybenzyl
analogues, is an orally active and selective noradrenaline reuptake
inhibitor that is presently recognized as a prescription drug in over
60 countries for depressive sickness and has been spaciously studied
for its pharmacological characteristics. (+)-(S,S)-Reboxetine is presently undergoing advanced clinical
evaluation as a potential treatment for neuropathic and fibromyalgia
pain. Scheming well-organized approaches to access reboxetine and
its derivatives represents a significant endeavor not only for developing
antidepressant drugs but also advancing medical studies by radiolabeling
of reboxetine derivatives with 11C, 18F, or 123I as potential positron emission tomography radioligands
for imaging the brain norepinephrine transporter system. Therefore,
to fulfill the challenge of creating the reboxetine architecture by
improved synthetic routes, the review combines all of the literature
synthetic processes for reboxetine and its derivatives on one platform.
Cons and pros of each synthetic method are discussed in this review,
which will be very fruitful for the synthetic and medical communities
to increase the diversity of synthetic procedures and to develop new
concepts and perceptions.